AstraZeneca a tricky takeover target after big cancer drug blow – Reuters
Reuters |
AstraZeneca a tricky takeover target after big cancer drug blow
Reuters Two other new cancer medicines, Tagrisso and Lynparza, are doing well, while its troubled immunotherapy drug Imfinzi should still be a significant seller for non-metastatic lung cancer, despite the big hit to the firm's chances in advanced disease. BMS takes AstraZeneca to court over cancer treatment |
